How much revenue does Innovent BIO make?

Innovent BIO reported 9.42 billion CNY in revenue for fiscal year 2024, up 51.8% from 6.21 billion CNY in fiscal year 2023.

Where does Innovent BIO make most of its revenue?

The People's Republic of China: 93% of revenue by region in fiscal year 2025, followed by Europe (4%).

What companies are similar to Innovent BIO?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Hansoh Pharmaceutical Group Company Limited (3692.HK), Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK), Akeso, Inc. (9926.HK), Shanghai Henlius Biotech, Inc. (2696.HK).

Innovent BIO (1801.HK) Stock

About Innovent BIO

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, an...

At a glance

Innovent BIO reported revenue of 9.42 billion CNY for fiscal year 2024, up 51.8% from fiscal year 2023, and net income of -94.63 million CNY. The People's Republic of China was its largest region in fiscal year 2025, with 93% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.